International Myeloma Working Group (IMWG) Summaries (https://www.myeloma.org/imwg-summaries)

The International Myeloma Working Group’s (IMWG) summaries focus on guidelines and statements about certain aspects of multiple myeloma. The IMWG's research on multiple myeloma studies its causes, how to stage the disease, and how to achieve remission. The following are a few of the topics that the IMWG covers: 

  • vertebral augmentation
  • treatment-emergent peripheral neuropathy
  • facilities and services for myeloma patients
  • using bisphosphonates

With new and upcoming information about myeloma and its treatments, the International Myeloma Working Group’s summaries clarify upcoming data in an easier way. These summaries also focus on myeloma’s classifications, different types of myeloma, what influences myeloma to become active as well as managing the side effects of treatment.

IMWG Guidelines for Serum Free Light Chain Analysis in Multiple Myeloma and Related Disorders (https://www.myeloma.org/resource-library/imwg-guidelines-serum-free-light-chain-analysis-multiple-myeloma-related-disorders)
The IMF's International Myeloma Working Group presents guidelines for serum-free light chain analysis in multiple myeloma and other related disorders…
International Myeloma Working Group (IMWG) Molecular Classification of Multiple Myeloma (https://www.myeloma.org/resource-library/international-myeloma-working-group-imwg-molecular-classification-multiple-myeloma)

The intent of this statement is to provide a biological classification of multiple myeloma and to establish the prognostic value of known genetic…

International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (https://www.myeloma.org/resource-library/international-myeloma-working-group-imwg-uniform-response-criteria-multiple)

The International Myeloma Working Group [(MWG) has established response criteria for myeloma. This criteria has been accepted by the myeloma…

IMWG Guidelines for the Prevention of Thalidomide and Lenalidomide-Associated Thrombosis in Myeloma (https://www.myeloma.org/resource-library/imwg-guidelines-prevention-thalidomide-lenalidomide-associated-thrombosis-myeloma)
The risk of VTE in cancer patients is greater than 7%; those with myeloma have the highest risk of thrombosis. The oral immunomodulatory drugs,…
Source URL: https://www.myeloma.org/imwg-summaries